Value through InnovationFebruary 04 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents


Boehringer Ingelheim’s Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer


U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)


Boehringer Ingelheim’s third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer


FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment


First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis


New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched


Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer


FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery


Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index

back 1 2 3 4 5 6 7 8 9 10